Transgene cancer, infectious news

Transgene plans to reduce its headcount by 120 (42%) to about 163 and focus on clinical development and translational R&D in oncology and infectious disease. The company will cease its pharmaceutical development and biomanufacturing but declined to disclose a timeline. Transgene said it received a proposal from ABL Inc., a U.S. subsidiary of its principal shareholder, Institut Merieux (Lyon, France), offering manufacturing and related positions to an undisclosed “significant” number of Transgene employees in Illkirch. ...